NEVANAC NEWS HIGHLIGHTS
Published Studies Related to Nevanac (Nepafenac Ophthalmic)
Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. [2008.04]
PURPOSE: To assess the effects of nepafenac on corneal epithelial healing time and pain control compared to placebo in patients undergoing photorefractive keratectomy (PRK) surgery... CONCLUSIONS: Treatment with nepafenac 0.1% significantly reduced postoperative pain immediately following surgery and had no significant adverse effect on time to reepithelialization compared to placebo.
Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. [2007.11]
PURPOSE: To compare the clinical, subjective, and objective outcomes of the use of 2 topical nonsteroidal antiinflammatory drugs--ketorolac tromethamine LS 0.4% (Acular) and nepafenac 0.1% (Nevanac)--in patients having cataract surgery. SETTING: Single-center private practice, Las Vegas, Nevada, USA... CONCLUSION: Ketorolac tromethamine was statistically significantly better than nepafenac in terms of patient satisfaction, compliance, and postoperative pain control.
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. [2007.09]
PURPOSE: To evaluate the aqueous humor concentrations and cyclooxygenase (COX) inhibitory activities of nepafenac, amfenac, ketorolac, and bromfenac after topical ocular administration of Nevanac (nepafenac 0.1%), Acular LS (ketorolac 0.4%), or Xibrom (bromfenac 0.09%). SETTING: Five private ophthalmology practices throughout the United States... CONCLUSION: Nepafenac showed significantly greater ocular bioavailability and amfenac demonstrated greater potency at COX-2 inhibition than ketorolac or bromfenac.
Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. [2007.07]
PURPOSE: To determine the prostaglandin E(2) (PGE(2)) levels and aqueous concentrations achieved with ketorolac 0.4% (Acular LS; Allergan, Inc, Irvine, California, USA) and nepafenac 0.1% (Nevanac; Alcon Laboratories, Inc, Fort Worth, Texas, USA). DESIGN: Single-center, randomized, double-masked study... CONCLUSIONS: Ketorolac 0.4% inhibited PGE(2) and penetrated into aqueous significantly more than nepafenac 0.1%.
Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. [2007.01]
PURPOSE: To determine whether nepafenac ophthalmic [generic for Nevanac] suspension 0.1% decreases the incidence and severity of inflammation and pain after cataract surgery with posterior chamber intraocular lens implantation. SETTING: Twenty-one ophthalmology clinics in the United States... CONCLUSION: Nepafenac ophthalmic suspension 0.1% was safe and effective for preventing and treating ocular inflammation and pain associated with cataract surgery.
Clinical Trials Related to Nevanac (Nepafenac Ophthalmic)
Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-Operative Cystoid Macular Edema. [Active, not recruiting]
This research is being done to look at the effects of Bromfenac, also called Xibrom for the
treatment of swelling in the retina (the light sensitive tissue in the back of the eye)
called "macular edema" that occurs after cataract surgery. Swelling in the retina can lead
to blurry vision.
The most commonly used treatment is eyedrops that decrease inflammation and may help stop
some of the swelling. We want to see if the drug Bromfenac(Xibrom) can decrease the swelling
in the retina after cataract surgery and improve vision in these patients.
Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK [Completed]
To determine the ability of two topical Nonsteroidal Anti-inflammatory drops (Acular LS &
Nevanac) to help control pain following Photorefractive Keratectomy (PRK).
Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT) [Not yet recruiting]
The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac
following SLT.
Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation [Recruiting]
The purpose of this study is to determine whether topical nepafenac (qid) is effective in
preventing and treating macular thickening related pan-retinal photocoagulation in patients
with diabetic retinopathy.
Nevanac 3-Month Safety Study With QID Dosing [Completed]
The purpose of this protocol is to determine the safety of Nevanac 0. 1% compared to Acular LS
0. 4% and Vehicle in patients treated before cataract surgery and for approximately 90 days
following surgery.
|
